A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
08/2011
08/30/2011	US8008270 Antiviral oligonucleotides targeting viral families
08/30/2011	US8008269 Antiviral oligonucleotides
08/30/2011	US8008268 Vaccines against vesicular stomatitis
08/30/2011	US8008267 Modified dinucleotides for reduce or improve immunostimulatory; genetic vaccines; cancer vaccines
08/30/2011	US8008266 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1
08/30/2011	US8008265 Vaccines, immunotherapeutics and methods for using the same
08/30/2011	US8008077 Photochemical internalization for delivery of molecules into the cytosol
08/30/2011	US8008076 Method of producing a nucleic acid encoding an antibody
08/30/2011	US8007997 Methods and compositions for inhibiting the growth of hematopoietic malignant cells
08/30/2011	US8007798 Treatment of complement-associated disorders
08/30/2011	US8007781 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
08/30/2011	US8007780 cystic fibrosis transmembrane conductance regulator (CFTR) gene; superoxide dismutase (SOD); primary pulmonary hypertension, pulmonary vascular disease secondarily associated with chronic airways obstruction, and connective tissue disease
08/30/2011	US8007779 Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
08/30/2011	US8007778 Use of calcium binding proteins to improve cardiac contractile function
08/30/2011	CA2498651C Nucleoside triphosphate diphosphohydrolase and uses thereof
08/30/2011	CA2405458C Herpes viruses for immune modulation
08/25/2011	WO2011103528A2 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
08/25/2011	WO2011103394A2 Methods for gene inhibition
08/25/2011	WO2011103345A2 Methods and compositions for influencing tumors using microrna-185 as a tumor suppressor
08/25/2011	WO2011103164A1 Monkey homolog of human interferon omega
08/25/2011	WO2011103011A2 Gene fusion targeted therapy
08/25/2011	WO2010148203A3 Producer cells for replication competent retroviral vectors
08/25/2011	US20110207985 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
08/25/2011	US20110207802 Glutamic acid decarboxylase (gad) based delivery system
08/25/2011	US20110207664 Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
08/25/2011	US20110207224 In vivo production of small interfering rnas that mediate gene silencing
08/25/2011	US20110207211 Expression of immunoglobulin-cytokine fusion proteins in malignant b cells
08/25/2011	US20110206755 Methods and products for manipulating uncoupling protein expression
08/25/2011	US20110206710 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
08/25/2011	US20110206682 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
08/25/2011	US20110206668 Methods and compositions for modulating immunity
08/25/2011	US20110206639 Replication competent viruses capable of silencing virus inhibitory factor expression
08/25/2011	CA2790506A1 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
08/24/2011	EP2360276A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
08/24/2011	EP2360260A1 BASB006 polynucleotide(s) and polypeptides from Neisseria meningitis
08/24/2011	EP2360253A1 RNA sequence-specific mediators of RNA interference
08/24/2011	EP2360252A1 Immunostimulatory nucleic acid molecules comprising GTCGTT motifs
08/24/2011	EP2360251A2 In vivo production of small interfering RNAs that mediate gene silencing
08/24/2011	EP2360250A2 siRNA for treatment of blood vessels
08/24/2011	EP2360169A2 PSMA antibodies
08/24/2011	EP2359869A2 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor
08/24/2011	EP2359868A1 Vector encoding human globulin gene and use thereof in treatment of hemoglobinopathies
08/24/2011	EP2359867A1 Method of increasing the function of an AAV vector
08/24/2011	EP2359866A1 Method of increasing the function of an AAV vector
08/24/2011	EP2359865A1 Method of increasing the function of an AAV vector
08/24/2011	EP2359854A1 Pharmaceutical compositions and methods useful for modulating angiogenesis
08/24/2011	EP2359853A1 Pharmaceutical compositions and methods useful for modulating angiogenesis
08/24/2011	EP2359840A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
08/24/2011	EP2359134A1 Methods for identifying modulating compounds of lymphangiogenesis, means therefore, compounds and uses thereof
08/24/2011	EP2358751A1 Truncated cd20 protein, deltacd20
08/24/2011	EP2358398A2 Oligomeric compounds and methods
08/24/2011	EP2358397A2 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
08/24/2011	EP2358386A2 Optimized influenza vaccines
08/24/2011	EP2358382A2 NOVEL USES OF VEGFxxxB
08/24/2011	EP1684736B1 Dna damage repair inhibitors for treatment of cancer
08/24/2011	EP1587923B1 Improved constructs for expressing lysosomal polypeptides
08/24/2011	EP1549735B1 Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
08/24/2011	EP1545625B1 Flexible vaccine assembly and vaccine delivery platform
08/24/2011	EP1499729B1 Derivatives of the nf-kappab inducing enzyme, their preparation and use
08/24/2011	EP1423404B1 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/24/2011	EP1025121B1 Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor
08/24/2011	CN102165061A Modulation of TOLL-like receptor 9 expression by antisense oligonucleotides
08/24/2011	CN102164618A Non-viral compositions and methods for transfecting gut cells in vivo
08/24/2011	CN102161998A Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof
08/24/2011	CN102161991A Single-strand multi-target interfering nucleic acid molecule and application thereof
08/24/2011	CN102160895A Application of PITPNM3 gene in preparing medicine for inhibiting breast cancer invasion and transfer
08/24/2011	CN102160894A Benzamide analog mediated brain-targeting delivery system
08/24/2011	CN101220372B Recombined bifidobacteria -hRV/VP7 expression vector and oral vaccine thereof
08/24/2011	CN101062947B Ciliary neurotrophy factor polypeptide allosteric and application thereof
08/23/2011	US8003779 Compositions and methods for studying and treating inflammatory diseases and disorders
08/23/2011	US8003776 Mycobacterial antigens expressed during latency
08/23/2011	US8003772 Chimeric PUFA polyketide synthase systems and uses thereof
08/23/2011	US8003758 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
08/23/2011	US8003734 Vectors for inserting nucleic acid into cells
08/23/2011	US8003622 Peptide biosynthesis and pain therapy
08/23/2011	US8003618 Focal calcium channel modulation
08/23/2011	US8003389 Mixture comprising mannitol for suspending animal or human cells and for dissolving biologically active molecules in order to introduce molecules into cells using electric current
08/23/2011	US8003113 DNA vaccine compositions and methods of use
08/23/2011	US8003109 Pharmaceutical compositions containing the long pentraxin PTX3
08/23/2011	CA2469053C Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
08/23/2011	CA2296807C Erbb4 receptor-specific neuregulin related ligands and uses therefor
08/23/2011	CA2238436C Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
08/18/2011	WO2011090740A9 Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
08/18/2011	US20110202033 Compositions and methods for the treatment and prevention of cardiac ischemic injury
08/18/2011	US20110201798 Therapeutic compositions
08/18/2011	US20110201677 Promoters exhibiting endothelial cell specificity and methods of using same
08/18/2011	US20110201673 Lpl variant therapeutics
08/18/2011	US20110201672 Semi-soft c-class immunostimulatory oligonucleotides
08/18/2011	US20110201670 Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
08/18/2011	US20110201115 Method and apparatus for production of a skin graft and the graft produced thereby
08/18/2011	US20110201107 Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and animals
08/18/2011	US20110201044 Tuberculosis diagnostic test
08/18/2011	US20110201029 Il-13 receptor antibodies
08/18/2011	US20110200677 Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
08/18/2011	US20110200576 Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
08/18/2011	US20110200564 Diagnosis and treatment of alzheimer's disease (ad)
08/17/2011	EP2357223A2 Human stem cell material and methods
08/17/2011	EP2357187A1 Molecules with extended half-lives, compositions and uses thereof
08/17/2011	EP2357010A1 Method of increasing the function of an AAV vector
08/17/2011	EP2357008A1 Albumin fusion proteins

1 ... 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 ... 870